Speaking of SurgOnc
Episodes
Rick Greene, MD, and Ken Tanabe, MD, discuss the need for surgical oncologists to remain focused on providing optimal care for our cancer patients while managing the demands that the COVID-19 pandemic continues to impose. Dr. Tanabe is author of, "Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change."
Dr. Tanabe is a Professor of Surgery at Harvard Medical School ...
Rick Greene, MD and Charlotte Ariyan, MD, PhD, discuss survival outcomes in patients with metastatic melanoma who were selected for surgery following checkpoint blockade. Dr. Ariyan is author of, “Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.”
Dr. Ariyan is Associate Professor of Surgery, Weill Cornell Medical College, and a Surgeon with clinical expertise in melanoma an...
Rick Greene, MD and Katie Egan, MD discuss the use of an educational intervention to decrease opioid consumption among breast surgery patients. Dr. Egan is author of the article, “Opioid Consumption Following Breast Surgery Decreases with a Brief Educational Intervention: A Randomized, Controlled Trial.”
Dr. Egan is Plastic and Reconstructive Surgery Resident at The University of Kansas Medical Center in Kansas City, KS.
Rick Green, MD and Dr. Anna Weiss, MD discuss clinical trials that have defined the role of neoadjuvant endocrine therapy in patients with estrogen receptor-positive breast cancer. Dr. Weiss is author of “The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer.”
Dr. Weiss is Assistant Professor of Surgery at Harvard Medical School, Boston, MA.
Rick Greene, MD, and Alexandra Gangi, MD and James Howe, MD, discuss current data regarding management of neuroendocrine liver metastases and future areas for study. Dr. Gangi and Dr. Howe are authors of “The Landmark Series: Neuroendocrine Tumor Liver Metastases.”
Dr. Gangi is Assistant Professor of Surgery in the Department of Surgical Oncology and the Director of the Gastrointestinal Tumor Program at Cedars-Sinai, Los Angeles, C...
Rick Greene, MD and Giorgos Karakousis, MD discuss the impact of immune checkpoint and BRAF/MEK pathway inhibitors on outcomes and melanoma care at a national population level in patients diagnosed with clinical stage III melanoma. Dr. Karakousis is author of, “Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.”
Dr. Karakousis is Associate Professor of Surgery at the Hospital of t...
Rick Greene, MD, and Michael D’Angelica, MD discuss the relationship between hepatic parenchymal disease and recurrence after colorectal liver metastases resection, which has not been well defined. Dr. D’Angelica is author of, “Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases.”
Dr. D’Angelica holds the Enid A. Haupt Chair in Surgery at Memorial Sloan Kettering Cancer ...
Rick Greene, MD and Elizabeth Grubbs, MD, MS discuss an analysis of the applicant pool of complex general surgical oncology (CGSO) fellowships and how it has changed over the last decade.
Dr. Grubbs is author of, “Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility.”
Dr. Grubbs is Associate Professor, Program Director of Complex General Surgical Oncology Fellow...
Rick Greene, MD and Julie Hallet, MD discuss the moderate-to-severe symptoms observed to steeply increase as death nears for patients with neuroendocrine tumors (NETs), which highlight an opportunity for improved management.
Dr. Hallet is author of, “Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes.”
Dr. Hallet is Assistant Professor, Surgical Oncolog...
Dr. Greene and Dr. Plichta discuss the potential benefit for women from genetic testing for BRCA1, BRCA2, and other breast cancer genes and the knowledge needed by breast surgeons to facilitate testing and counseling.
Dr. Plichta is author of, “Germline Genetic Testing: What the Breast Surgeon Needs to Know.”
Dr. Plichta is an Assistant Professor of Surgery, Division of Surgical Oncology, Duke Surgery, Duke University School of Me...
Rick Greene, MD and Marissa M. Howard-McNatt, MD discuss how the requirements for maintenance of certification (MOC) and CME changed in 2018, and review the options for completing these requisites.
Mariss M. Howard-McNatt, MD is author of, “Maintenance of Certification and Continuing Medical Education: Are They Still Required?”
Marissa M. Howard-McNatt, MD is an Associate Professor of Surgery Sciences – Oncology, Wake Forest School...
Dr. Greene and Dr. Jeruss discuss the potential impact of treatment on the future fertility of young breast cancer patients and review guidelines provided to address reproductive health in conjunction with a breast cancer diagnosis.
Dr. Jeruss is author of, “Young Women with Breast Cancer: Fertility Preservation Options and Management of Pregnancy-Associated Breast Cancer.”
Dr. Jeruss is an Associate Professor of Surgery at Departm...
Dr. Rick Greene and Dr. Andrew J. Rosko discuss how intraoperative usage of indocyanine green imaging can predict the formation of post-operative fistulas, allowing for more tailored reconstructive options depending on risk of fistula.
Dr. Rosko is author of, “Intraoperative Fluorescent Angiography Predicts Pharyngocutaneous Fistula After Salvage Laryngectomy.”
Dr. Rosko is a Clinical Assistant Professor, Department of Otolaryngolo...
Dr. Rick Greene and Dr. Paxton Dickson discuss adrenocortical carcinoma and related issues regarding adjuvant and neoadjuvant therapy, treatment of advanced disease, and genetic considerations for patients who have this disease.
Dr. Dickson is author of, “Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disea...
Dr. Rick Greene and Dr. Clancy Clark discuss the use of a modified frailty index as a predictor in pancreaticoduodenectomy, its association with postoperative morbidity and mortality, and how it can aid in preoperative risk stratification.
Dr. Clark is author of, “Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy.”
Dr. Clark is an Assistant Professor, Department of Surgery, at Wake Forest Baptist...
Dr. Rick Greene and Dr. Basem Azab discuss the relationship of the interval between neoadjuvant chemoradiation-to-surgery in the treatment of esophageal cancer, and associated pathological complete response rate and overall survival rate.
Dr. Azab is author of the Annals of Surgical Oncology article “Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophagea...
Dr. Greene and Dr. Pawlik will discuss the 8th edition of the TNM staging system for pancreas and hepatobiliary cancers, which affirms that the anatomic extent of disease remains the strongest predictor of outcome in hepatobiliary cancers.
Dr. Pawlik is ASO Deputy Editor and Editorial Board Section Editor, Hepatobiliary Tumors. He is co-author with Yun Shin Chun and Jean-Nicolas Vauthey of the ASO TNM staging editorial, "8th Ed...
Dr. Greene and Dr. Edge will discuss the TNM staging system and its relevance to breast cancer management.
Dr. Edge was Editor-in-Chief of the 7th Edition of the AJCC Cancer Staging Manual published in 2009 and co-author with Armando E. Giuliano and Gabriel N. Hortobagyi of the ASO editorial, “Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer”
Dr. Edge is the Vice President for Healthcare Outcomes Policy and Professor...
Dr. Greene and Dr. Gershenwald discuss the 8th edition of the TNM staging system for melanoma, and its use for communication between physicians and their patients as well as its impact on decision-making and prognostic assessment.
Dr. Gershenwald is co-author with Richard A. Scolyer of the ASO TNM staging editorial, “Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.”
Dr. Gershenwald is a surgical o...
Dr. Greene and Dr. Byrd discuss the 8th edition of the TNM staging system, which through its advances supports the concept of a team approach to cancer staging by clinical oncologists including cancer registrars, pathologists, and radiologists.
Dr. Byrd is co-author with Dr. Greene of the ASO TNM staging editorial, “The Eighth Edition of TNM: Implications for the Surgical Oncologist.”
Dr. Byrd is the Chair of the American Joint Com...